01627nas a2200133   4500008004100000245005100041210005000092260000800142300001400150490000600164520122300170100001701393856008301410       2016                        eng d00aRacemic drug resolution: a comprehensive guide0 aRacemic drug resolution a comprehensive guide  cOCT  a7567-75860 v83 aThe human body is amazingly chirally selective, and consequently enantiopure drugs are essential for treating disease. Nearly 50% of drugs are chiral wherein pharmacological activity resides with the eutomer (pharmacologically active enantiomer) whereas the distomer (inactive/less potent/equally potent/different pharmacological activity/toxic enantiomer) metabolizes by a different pathway and creates unnecessary burden on the body. A teratogenic (toxic) isomer in a racemic drug creates sideeffects, genetic diseases, or may cause death in the case of high dosage. Nowadays, market approval of enantiopure drugs has increased exponentially whereas it has tremendously decreased for racemic and achiral drugs. An expensive process is the main drawback in obtaining enantiopure drugs. Different methods such as chromatography, spectroscopy, and thermal analysis are available for optical purity determination. However, only a few chromatographic methods are useful on an industrial scale. In the present review, racemic resolution and optical purity determination methods are discussed with examples. In addition to this, eutomers and distomers of different drugs containing a single chiral center are also reported.1 aMane, Sachin  uhttps://library.ncl.res.in/content/racemic-drug-resolution-comprehensive-guide